ALKgene expression status in pleural effusion predicts tumor responsiveness to crizotinib in Chinese patients with lung adenocarcinoma.
OBJECTIVE
The relationship between anaplastic lymphoma kinase (ALK) expression in malignant pleural effusion (MPE) samples detected only by Ventana immunohistochemistry (IHC) ALK (D5F3) and the efficacy ofALK-tyrosine kinase inhibitor therapy is uncertain.


METHODS
Ventana anti-ALK (D5F3) rabbit monoclonal primary antibody testing was performed on 313 cell blocks of MPE samples from Chinese patients with advanced lung adenocarcinoma, and fluorescencein situhybridization (FISH) was used to verify theALKgene status in Ventana IHC ALK (D5F3)-positive samples. The follow-up clinical data on patients who received crizotinib treatment were recorded.


RESULTS
Of the 313 MPE samples, 27 (8.6%) were confirmed asALKexpression-positive, and the Ventana IHC ALK (D5F3)-positive rate was 17.3% (27/156) in wild-type epidermal growth factor receptor (EGFR) MPE samples. Twenty-three of the 27 IHC ALK (D5F3)-positive samples were positive by FISH. Of the 11 Ventana IHC ALK (D5F3)-positive patients who received crizotinib therapy, 2 patients had complete response (CR), 5 had partial response (PR) and 3 had stable disease (SD).


CONCLUSIONS
TheALKgene expression status detected by the Ventana IHC ALK (D5F3) platform in MPE samples may predict tumor responsiveness to crizotinib in Chinese patients with advanced lung adenocarcinoma.
Department of Pathology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China.
Zheng
Z
Wang
Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China.
Xiaonan
X
Wu
Department of Medical Oncology, National Cancer Center/Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
Xiaohong
X
Han
Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China.
Gang
G
Cheng
Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China.
Xinlin
X
Mu
Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
Yuhui
Y
Zhang
Department of Pathology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China.
Di
D
Cui
Department of Medical Oncology, PLA Army General Hospital, Beijing 100700, China.
Chang
C
Liu
Department of Pathology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China.
Dongge
D
Liu
Department of Medical Oncology, National Cancer Center/Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
Yuankai
Y
Shi
Anaplastic lymphoma kinase; crizotinib; fluorescence in situ hybridization; immunohistochemistry; lung adenocarcinoma; pleural effusion